Ralf Bauer
University Hospital Heidelberg
19 Papers
63 Citations
Ralf Bauer is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Cardiac amyloidosis & Cardiomyopathy. The author has an hindex of 9, co-authored 19 publications. Previous affiliations of Ralf Bauer include Heidelberg University.
Chat about Author
Papers
Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis
Arnt V. Kristen,Eva Brokbals,Fabian aus dem Siepen,Ralf Bauer,Selina Hein,Matthias Aurich,Johannes Riffel,Hans-Michael Behrens,Sandra Krüger,Peter Schirmacher,Hugo A. Katus,Christoph Röcken +11 more
TL;DR: Early identification of subjects with AL amyloid is essential given that in late-stage disease with extensive amyloids load, the authors' data suggested that outcomes are not affected by administration of chemotherapy.
89
Noninvasive Risk Stratification of Patients With Transthyretin Amyloidosis
Arnt V. Kristen,Katrin Scherer,Sebastian J. Buss,Fabian aus dem Siepen,Sabine Haufe,Ralf Bauer,Katrin Hinderhofer,Evangelos Giannitsis,Stefan E. Hardt,Uwe Haberkorn,Hugo A. Katus,Henning Steen +11 more
TL;DR: Quantitative analysis of tracer retention is capable of characterizing the severity of cardiac involvement in ATTR, and troponin T remained the only independent predictor of survival.
57
Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?
TL;DR: Investigating the outcome of ATTR patients on different combinations of medication retrospectively and the use of ACEi and beta-blockers in cardiac transthyretin amyloidosis has not been elucidated in detail is sought.
36
TIP30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation.
Andrea Grund,Andrea Grund,Malgorzata Szaroszyk,Mortimer Korf-Klingebiel,Mona Malek Mohammadi,Mona Malek Mohammadi,Felix A. Trogisch,Ulrike Schrameck,Anna Gigina,Christopher Tiedje,Matthias Gaestel,Theresia Kraft,Jan Hegermann,Sandor Batkai,Thomas Thum,Andreas Perrot,Cris dos Remedios,Eva Riechert,Mirko Völkers,Shirin Doroudgar,Andreas Jungmann,Ralf Bauer,Xiaoke Yin,Manuel Mayr,Kai C. Wollert,Andreas Pich,Hua Xiao,Hugo A. Katus,Johann Bauersachs,Oliver J. Müller,Joerg Heineke +30 more
TL;DR: Mechanistically, TIP30 binds the eukaryotic elongation factor 1A (eEF1A) to prevent the interaction with its essential co‐factor eEF1B2 and translational elongation and could be a therapeutic target to counteract cardiac hypertrophy.
25
Peak V’O2 is an independent predictor of survival in patients with cardiac amyloidosis
TL;DR: Cutting peak V’O2 below median value is identified as an independent predictor of mortality in patients with cardiac involvement in different forms of systemic amyloidosis and these patients tend to have more pronounced impairment of longitudinal function.
19